Quick Read – AI cuts drug discovery from years to weeks, targeting a 10-15 year pipeline where 90% of candidates never reach market approval. – Eli Lilly’s tirzepatide franchise generated $36.5 billion in 2025 revenue, a gain of 215%, while Novo Nordisk’s GLP-1 portfolio reached…
4.6 billion. – Schrodinger’s physics-based simulation software serves 18 of the world’s 20 largest pharma companies, posting 12% revenue growth in Q1 2026. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation.
By treating drug discovery as a massive optimization problem, AI can analyze millions of molecular combinations in weeks instead of years, dramatically shortening the path from concept to clinical testing. Few areas stand to benefit more than peptide-based medicines. These short chains of amino acids occupy a sweet spot between traditional small-molecule drugs and complex biologics.